TY - JOUR
T1 - Are We There Yet? Short-Course Regimens in TB and HIV
T2 - From Prevention to Treatment of Latent to XDR TB
AU - Ignatius, Elisa H.
AU - Swindells, Susan
N1 - Funding Information:
Elisa Ignatius is supported by T32 GM066691-17. Susan Swindells reports research grants to her institution from ViiV Healthcare and the National Institutes of Health.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - Purpose of Review: Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV. Recent Findings: After many years without new agents, there is now active testing of many novel drugs to treat TB, both for latent infection and active disease. Though not all studies have included patients with HIV, many have, and there are ongoing trials to address key implementation challenges such as potent drug-drug interactions with ART. Summary: The goal of short-course regimens for TB is to enhance treatment completion without compromising efficacy. Particularly among patients with HIV, studying these shortened regimens and integrating them into clinical care are of urgent importance. There are now multiple short-course regimens for latent infection and active disease that are safe and effective among patients with HIV.
AB - Purpose of Review: Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV. Recent Findings: After many years without new agents, there is now active testing of many novel drugs to treat TB, both for latent infection and active disease. Though not all studies have included patients with HIV, many have, and there are ongoing trials to address key implementation challenges such as potent drug-drug interactions with ART. Summary: The goal of short-course regimens for TB is to enhance treatment completion without compromising efficacy. Particularly among patients with HIV, studying these shortened regimens and integrating them into clinical care are of urgent importance. There are now multiple short-course regimens for latent infection and active disease that are safe and effective among patients with HIV.
KW - Drug-drug interactions
KW - Drug-resistant tuberculosis
KW - Drug-susceptible tuberculosis
KW - HIV infection
KW - Tuberculosis
KW - Tuberculosis preventive therapy
UR - http://www.scopus.com/inward/record.url?scp=85090956629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090956629&partnerID=8YFLogxK
U2 - 10.1007/s11904-020-00529-8
DO - 10.1007/s11904-020-00529-8
M3 - Review article
C2 - 32918195
AN - SCOPUS:85090956629
SN - 1548-3568
VL - 17
SP - 589
EP - 600
JO - Current HIV/AIDS Reports
JF - Current HIV/AIDS Reports
IS - 6
ER -